TY - JOUR
T1 - Trial watch
T2 - Radioimmunotherapy for oncological indications
AU - Bloy, Norma
AU - Pol, Jonathan
AU - Manic, Gwenola
AU - Vitale, Ilio
AU - Eggermont, Alexander
AU - Galon, Jérôme
AU - Tartour, Eric
AU - Zitvogel, Laurence
AU - Kroemer, Guido
AU - Galluzzi, Lorenzo
N1 - Publisher Copyright:
© 2014 Taylor & Francis Group, LLC.
PY - 2014/10/1
Y1 - 2014/10/1
N2 - During the past two decades, it has become increasingly clear that the antineoplastic effects of radiation therapy do not simply reflect the ability of X-, β- and γ-rays to damage transformed cells and directly cause their permanent proliferative arrest or demise, but also involve cancer cell-extrinsic mechanisms. Indeed, among other activities, radiotherapy has been shown to favor the establishment of tumor-specific immune responses that operate systemically, underpinning the so-called ‘out-of-field’ or ‘abscopal’ effect. Thus, ionizing rays appear to elicit immunogenic cell death, a functionally peculiar variant of apoptosis associated with the emission of a particularly immunostimulatory combination of damage-associated molecular patterns. In line with this notion, radiation therapy fosters, and thus exacerbates, the antineoplastic effects of various treatment modalities, including surgery, chemotherapy and various immunotherapeutic agents. Here, we summarize recent advances in the use of ionizing rays as a means to induce or potentiate therapeutically relevant anticancer immune responses. In addition, we present clinical trials initiated during the past 12 months to test the actual benefit of radioimmunotherapy in cancer patients.
AB - During the past two decades, it has become increasingly clear that the antineoplastic effects of radiation therapy do not simply reflect the ability of X-, β- and γ-rays to damage transformed cells and directly cause their permanent proliferative arrest or demise, but also involve cancer cell-extrinsic mechanisms. Indeed, among other activities, radiotherapy has been shown to favor the establishment of tumor-specific immune responses that operate systemically, underpinning the so-called ‘out-of-field’ or ‘abscopal’ effect. Thus, ionizing rays appear to elicit immunogenic cell death, a functionally peculiar variant of apoptosis associated with the emission of a particularly immunostimulatory combination of damage-associated molecular patterns. In line with this notion, radiation therapy fosters, and thus exacerbates, the antineoplastic effects of various treatment modalities, including surgery, chemotherapy and various immunotherapeutic agents. Here, we summarize recent advances in the use of ionizing rays as a means to induce or potentiate therapeutically relevant anticancer immune responses. In addition, we present clinical trials initiated during the past 12 months to test the actual benefit of radioimmunotherapy in cancer patients.
KW - CTLA4
KW - Dendritic cells
KW - Ibritumomab tiuxetan
KW - Immunostimulatory cytokines
KW - Peptide-based anticancer vaccine
KW - Toll-like receptor agonists
UR - http://www.scopus.com/inward/record.url?scp=84934317841&partnerID=8YFLogxK
U2 - 10.4161/21624011.2014.954929
DO - 10.4161/21624011.2014.954929
M3 - Review article
AN - SCOPUS:84934317841
SN - 2162-4011
VL - 3
JO - Oncoimmunology
JF - Oncoimmunology
IS - 9
M1 - e954929
ER -